Shubham Khandve/LinkedIn

Nov 8, 2025, 01:40

Shubham Khandve: Cell and Gene Therapy is No Longer the Future

Shubham Khandve, Manager at Spherical Insights LLP, shared on LinkedIn:

”Cell and gene therapy is no longer the future.
Download PDF Brochure.

It’s here – and it’s transforming medicine in real time.

The FDA has now approved dozens of therapies that repair, replace, or reprogram human cells.

Each one represents a shift from treating symptoms to correcting the root cause.

The largest category is hematologic, covering diseases like lymphoma, multiple myeloma, and hemophilia.
Oncology is next, led by CAR-T cell therapies like Kymriah, Yescarta, and Breyanzi.
Neurologic treatments such as Zolgensma and Skysona are rewriting outcomes for genetic disorders once considered untreatable.
Ophthalmologic and dermatologic approvals, like Luxturna and Vyjuvek, restore vision and skin integrity at the genetic level.

Every name on this chart represents years of research, clinical trials, and the hope of a cure – not just control.

Cell and gene therapy is moving medicine from management to molecular repair.

This is the start of a new era in healthcare.

Cell and gene therapy isn’t coming – it’s here.

The FDA has approved dozens of treatments that repair rather than manage disease.

We’re entering the age of molecular medicine, where the cure is written into your cells.”

Shubham Khandve